secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-117669
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel posts Q3 net loss $50.5M, aligns with FDA on Phase 3 for agitation in Alzheimer's dementia
--------------------------------------------------------------------------------

- Q3 net loss $50.5M vs $41.8M YoY; IGALMI net revenue ~$341k; cash $90M, funds through mid-2024.
- FDA alignment for Phase 3 trial of BXCL501 (60 mcg) for Alzheimer's agitation in at-home setting; ~100 patients, 4 weeks.
- SERENITY III program plans Phase 3 trial with 120 mcg dose (approved IGALMI dose) for at-home agitation in bipolar/schizophrenia.
- Binding term sheet with Oaktree and QIA to amend financing; potential access to more capital, adjusted revenue covenants.
- OnkosXcel reports positive Phase 2 overall survival for BXCL701 in prostate cancer; evaluating strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/0001104659-23-117669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/tm2330471d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer